Gynecologic Cancers | Clinical

New Metastatic Cervical Cancer Treatments Give Hope

January 21, 2021

Investigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.

Expert Highlights Latest Advances, Ongoing Trials During Cervical Cancer Awareness Month

January 08, 2021

Noelle G. Cloven, MD, discussed the current cervical cancer treatment paradigm, the unmet needs that still remain to be addressed, and encouraging new directions of research in clinical trials in honor of Cervical Cancer Awareness Month.

Novel HPV Vaccine Shows Reduced High-Grade Squamous Intraepithelial Lesions in Women

January 06, 2021

VGX-3100, a therapeutic DNA vaccine, achieved a 25% reduction or more reduction in HPV-16/18-associated vulvar high-grade squamous intraepithelial lesion in 63% of patients at 6 months after treatment with the agent, according to findings from an open-label phase 2 clinical trial.

Rucaparib Improves PFS in Patent With BRCA Mutation-Positive Relapsed Ovarian Cancer

December 21, 2020

Treatment with rucaparib led to an improvement in investigator-assessed progression-free survival compared with chemotherapy in patients with relapsed ovarian cancer with a BRCA mutation who have received 2 or more prior lines of chemotherapy, meeting the primary end point of the phase 3 ARIEL4 clinical trial.

Pembrolizumab Plus Lenvatinib Significantly Improves Survival in Advanced Endometrial Cancer

December 17, 2020

Pembrolizumab plus lenvatinib induced a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with advanced endometrial cancer after prior systemic therapy in the phase 3 KEYNOTE-775/Study 309 trial.

Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors

November 17, 2020

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.